Clear Impact logo

End Hep C SF Evaluation Dashboard

R
Time Period
Current Actual Value
Current Trend
Baseline % Change
Why Is This Important?

Morbidity refers to the rate of disease in a population. A reduction in morbidity (illness) due to HCV would mean that fewer people in San Francisco are suffering from the impact of an HCV infection. Illnesses caused by HCV could include things such as cirrhosis and fibrosis of the liver as well as liver cancer. 

I
2022
1,283
8
-62%
R
Time Period
Current Actual Value
Current Trend
Baseline % Change
Why Is This Important?

Mortality refers to deaths caused by HCV. A reduction in mortality would show us that San Francisco is making progress toward preventing new HCV infections and/or increasing access to treatment for HCV. 

I
2021
40
2
-39%
I
2021
6.7
1
-21%
P
Time Period
Current Actual Value
Current Trend
Baseline % Change
What We Do
Partners
PM
Q4 2020
28
2
-59%
PM
Q4 2021
85
3
-8%
P
Time Period
Current Actual Value
Current Trend
Baseline % Change
What We Do
Partners
PM
Q4 2023
216
1
-86%
P
Time Period
Current Actual Value
Current Trend
Baseline % Change
What We Do
Partners
PM
2023
145
1
1%
P
Time Period
Current Actual Value
Current Trend
Baseline % Change
Why Is This Important?

Any person who has ever had HCV will produce a "reactive" result in an antibody test, including people with active HCV infections, people who cleared it on their own without treatment, and those who have been cured through treatment. If a client has a reactive HCV Antibody test they are then referred to confirmatory HCV RNA testing that will show whether they have an active infection that requires treatment or a former infection that doesn't require treatment. Once people get treated they are unable to spread the virus which helps us to turn the curve on the number of new HCV infections (incidence) as well the total number of HCV cases in San Francisco (prevalence). Increasing the number of antibody tests is one of End Hep C SF's primary goals because it means that we are testing more people who are at risk for HCV and linking more people to RNA testing and HCV treatment.

PM
Q4 2023
56
2
-74%
PM
Q4 2023
6.1%
1
-36%
P
Time Period
Current Actual Value
Current Trend
Baseline % Change
Why Is This Important?
PM
Q4 2023
20
2
-71%

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy